Health Care · Biotechnology
Biogen: revenue, profit and cash flow
In fiscal 2025, Biogen had revenue of $9.89B, down 0.8% a year on average since 2015, and net income of $1.29B (13.1% of revenue). It has 36% fewer shares than in 2015.
Revenue, fiscal 2025
average annual revenue growth since 2015 · +2.2% vs 2024
- Ticker
- BIIB · Nasdaq
- Sector
- Health Care
- Sub-industry
- Biotechnology
- Headquarters
- Cambridge, Massachusetts
- Founded
- 1978
- In the S&P 500 since
- November 13, 2003
- Latest fiscal year
- 2025, ended December 31, 2025
- SEC filer
- Biogen Inc. · CIK 0000875045
Revenue and net income
Revenue went from $3.17B in 2007 to $9.89B in 2025.
Diluted earnings per share
Diluted EPS went from $1.99 in 2007 to $8.79 in 2025. Ten-year growth: −5.4% a year.
Shares outstanding
36.4% fewer shares in 2025 than in 2015 (231M → 147M): buybacks outweighed new shares.
Operating cash flow, capex and free cash flow
Free cash flow (operating cash flow minus capital expenditure) was $2.05B in 2025, 20.7% of revenue.
The chart data could not be loaded. The table below has the same figures.
Year by year
| Fiscal year | Revenue | Net income | Net margin | Diluted EPS | Shares | Operating cash flow | Capex | Free cash flow |
|---|---|---|---|---|---|---|---|---|
| 2025 | $9.89B | $1.29B | 13.1% | $8.79 | 147M | $2.2B | $154M | $2.05B |
| 2024 | $9.68B | $1.63B | 16.9% | $11.18 | 146M | $2.88B | $154M | $2.72B |
| 2023 | $9.84B | $1.16B | 11.8% | $7.97 | 146M | $1.55B | $277M | $1.27B |
| 2022 | $10.2B | $3.05B | 29.9% | $20.87 | 146M | $1.38B | $240M | $1.14B |
| 2021 | $11B | $1.56B | 14.2% | $10.40 | 150M | $3.64B | $258M | $3.38B |
| 2020 | $13.4B | $4.0B | 29.8% | $24.80 | 161M | $4.23B | $425M | $3.81B |
| 2019 | $14.4B | $5.89B | 41.0% | $31.42 | 187M | $7.08B | $514M | $6.56B |
| 2018 | $13.5B | $4.43B | 32.9% | $21.58 | 205M | $6.19B | $771M | $5.42B |
| 2017 | $12.3B | $2.54B | 20.7% | $11.92 | 213M | $4.55B | $867M | $3.68B |
| 2016 | $11.4B | $3.7B | 32.3% | $16.93 | 219M | $4.59B | $616M | $3.97B |
| 2015 | $10.8B | $3.55B | 33.0% | $15.34 | 231M | $3.92B | $643M | $3.28B |
| 2014 | $9.7B | $2.93B | 30.2% | $12.37 | 237M | $2.94B | $288M | $2.65B |
| 2013 | $6.93B | $1.86B | 26.9% | $7.81 | 238M | $2.35B | $246M | $2.1B |
| 2012 | $5.52B | $1.38B | 25.0% | $5.76 | 240M | $1.88B | $255M | $1.63B |
| 2011 | $5.05B | $1.23B | 24.5% | $5.04 | 245M | $1.73B | $208M | $1.52B |
| 2010 | $4.72B | $1.01B | 21.3% | $3.94 | 255M | $1.62B | $173M | $1.45B |
| 2009 | $4.38B | $970M | 22.2% | $3.35 | 289M | $1.07B | $166M | $909M |
| 2008 | $4.1B | $783M | 19.1% | $2.65 | 295M | $1.56B | $276M | $1.29B |
| 2007 | $3.17B | $638M | 20.1% | $1.99 | 320M | $1.02B | $284M | $735M |
Fiscal years, labelled by the year in which they end. US dollars; per-share figures and share counts adjusted for splits. —: not in the data.
About these figures
- No dividends per share in the filings data. Usually that means no dividend, but some companies report theirs in a form the data do not capture.
- Older years are as filed at the time and may predate later restatements, mergers or spin-offs. How the figures are made.
Other Biotechnology companies
Source: SEC EDGAR (company filings), data as of November 8, 2026. Sectors, sub-industries, headquarters and index dates: Wikipedia, CC BY-SA 4.0.